Biofrontera

Biofrontera AG engages in the research, development, and marketing of dermatological products. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biofrontera AG (BFRA) CEO Hermann Lübbert on Q2 2019 Results - Earnings Call Transcript

Leverkusen, Germany, Aug.  27, 2019  (GLOBE NEWSWIRE) --  Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its results for the first six months ended June 30, 2019. At the same time, Biofrontera provided an update on recent business developments.

Biofrontera shows robust growth during first six months of 2019

Biofrontera is shifting from a biotech company to a pharmaceutical company.

Biofrontera: The Battle For Ownership

Biofrontera is a hot dermatological biopharmaceutical company.

Biofrontera: Takeover Battle In Sight?

Biofrontera AG (BFRA) CEO Hermann Lübbert on Q1 2019 Results - Earnings Call Transcript

Biofrontera AG (BFRA) CEO Hermann Lübbert on Q4 2018 Results - Earnings Call Transcript

News for Biofrontera Stock (BFRA)